Meribank Biotech Co P/FCF

Que fait Meribank Biotech Co ? Meribank Biotech Co Ltd, listed on the Taiwan Stock Exchange with ticker 4724.TWO and ISIN TW0004724000, is headquartered in Taipei City, Taiwan. The company went public on June 16, 2023. Meribank Biotech focuses on the research and development of stem cell technologies, specifically providing cord blood (hematopoietic stem cells) storage and application services. It also offers storage and application services for placenta and umbilical cord (mesenchymal stem cells), as well as peripheral blood stem cell storage and application services. The company is involved in promoting stem cell transplantation applications and developing new stem cell processing technologies. Additionally, Meribank Biotech engages in the development of allogeneic umbilical cord mesenchymal stem cell manufacturing and therapeutic applications. The firm’s website is https://www.meribank.com.tw/. No further details on its sector, industry, or specific financial figures are provided in the available information. The company operates within the biotechnology sector, concentrating on stem cell-related services and technologies. Its IPO date marks its entry into the public market, with operations centered on the storage and application of various stem cell types for medical and therapeutic purposes. Meribank Biotech Co est l'une des entreprises les plus populaires sur Eulerpool.